Comparison of the In-House Made Carba-NP and Blue-Carba Tests: Considerations for Better Detection of Carbapenemase-producing *Enterobacteriaceae*

João Pires,[1,2] Regula Tinguely,[1] Bodmer Thomas,[3] Francesco Luzzaro,[4] and Andrea Endimiani [1*]

[1] Institute for Infectious Diseases, University of Bern, Bern, Switzerland; [2] Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland; [3]labormedizinisches zentrum Dr Risch, Department of Medical Microbiology, Bern-Liebefeld, Switzerland; [4]Laboratory of Microbiology, A. Manzoni Hospital, Lecco, Italy

Running title: In-house made Carba-NP *versus* Blue-Carba test

Keywords: Carbapenemases, carbapenems, diagnostics, MIC, *Klebsiella*, OXA-48, NDM, VIM, MBL

*__Corresponding authors__:
Prof. Andrea Endimiani MD, PhD
Institute for Infectious Diseases, University of Bern
Friedbühlstrasse 51, CH-3010, Bern, Switzerland
Phone: +41-31-632-8632; Fax: +41-31-632-8766
Emails: andrea.endimiani@ifik.unibe.ch; aendimiani@gmail.com

ABSTRACT

The in-house Carba-NP and Blue-Carba tests were compared using 30 carbapenemase- and 33 non-producing *Enterobacteriaceae*. Tests were read by three operators. 100% sensitivity was reported for both tests, but Carba-NP was slightly more specific than Blue-Carba (98.9% *vs.* 91.7%). We describe potential sources of error during tests' preparation and reading.

The continuous worldwide expansion of carbapenemase-producing *Enterobacteriaceae* (CPE) is a serious concern as infections caused by these pathogens have an increased mortality, morbidity, and associated health-care costs (Tängdén and Giske, 2015). Treatment options for CPE infections are often limited, since these organisms usually co-carry resistant determinants to other classes of antibiotics (Tängdén and Giske, 2015). Moreover, the heterogeneity of carbapenemase classes and types leads to a multiplicity of diverse carbapenem hydrolytic efficiencies and resistance phenotypes (Hrabák et al., 2014, Tängdén and Giske, 2015). Since carbapenem resistance mediated by carbapenemase production is continuously rising in *Enterobacteriaceae*, rapid, inexpensive, and reliable methods are urgently needed to identify CPE (Dortet et al., 2014).

Carba-NP and Blue-Carba are recent quick biochemical methods that detect carbapenemase activity when the enzyme breaks imipenem's β-lactam ring, leading to a pH decrease and consequent color shift of the pH-indicator in solution (Nordmann et al., 2012, Pires et al., 2013). Both methods proved to be fast (detection observed ≤2 hours), highly sensitive, specific and very cheap. Further studies have evaluated both tests, emphasizing their reproducibility, high sensitivity and specificity (Pasteran et al., 2015, Vasoo et al., 2013). However, others have questioned the utility of these methodologies (Tijet et al., 2013). Moreover, studies comparing the performance of the two tests are still scarce and those evaluating the impact of operators' experience in reading and interpreting results are lacking.

Since commercial tests have been just launched into the market (Novais et al., 2015, Poirel and Nordmann, 2015), we aim to compare the in-house made Carba-NP and Blue-Carba tests using a characterized collection of carbapenemase producing and non-producing *Enterobacteriaceae* in order to further identify potential sources of error.

Sixty-one previously characterized *Enterobacteriaceae* from different sources and countries (CPE, n=30, including 9 NDM, 10 OXA-48, 5 KPC, 3 NDM plus OXA-48, 2 VIM, and 1 IMP producers; non-CPE, n=33) recovered from cation adjusted Mueller-Hinton agar (Becton-Dickinson) were tested using Carba-NP and Blue-Carba, as previously described (Nordmann, Poirel and Dortet, 2012, Pires, Novais and Peixe, 2013). Both assays were executed in parallel two times each in non-consecutive days. Tests were performed and read by two different operators with previous experience in both assays (OP1 and OP2); a third operator (OP3) with no previous experience also read the results. Results were reported after 2 hours. Operators were blind regarding the species and *bla* gene content. Positive results were classified as "+", weak positive; "++", positive; and "+++", strong positive. MICs for imipenem, meropenem and ertapenem were assessed using Etest (bioMérieux) or microdilution ESB1F panels (Trek Diagnostics Systems).

As shown in Table 1, an overall sensitivity of 100% was obtained for both assays; however, Carba-NP revealed a higher specificity than Blue-Carba (98.9% *vs*. 91.7%, respectively). These high sensitivity and specificity for both tests are consistent with previous reports (Pasteran, Veliz, Ceriana, Lucero, Rapoport, Albornoz, Gomez and Corso, 2015, Pires, Novais and Peixe, 2013, Vasoo, Cunningham, Kohner, Simner, Mandrekar, Lolans, Hayden and Patel, 2013, Yusuf et al., 2014).

For Carba-NP, interpretation was more homogeneous, with OP1 interpreting correctly all isolates, while OP2 and OP3 identified one false-positive result only in the first assay. Blue-Carba's interpretation was similar for OP1 and OP2, whereas OP3 interpreted more false-positive results yielding a lower specificity (i.e., 96.9% for OP1 and OP2 *vs*. 89.4% for OP3). Nevertheless, false-positive results read by OP3 decreased in the second assay (i.e., from 5 to 2). This emphasizes the fact that both tests are easy

to interpret even for less experienced operators and that misinterpretations rapidly decrease over time. Nonetheless, the variability of the intensities reported by the different operators also highlights the increased subjectivity of both methods (Table 1).

For both tests, all false-positive results were classified as weak positives ("+"). A false-positive strain was consistently found by all operators with the Blue-Carba assays for an ACT-1-producing *E. coli*. Previous kinetic studies have shown that the plasmid-mediated AmpC (pAmpC) ACT-1 hydrolyzes slowly imipenem (Mammeri et al., 2010). It is to note that kinetic experiments have a much shorter time span compared to both tests. Additionally, we hypothesize that false-positive results can arise when different inoculum amounts are used in the test and the negative control solutions. This could explain the misclassification of the pAmpC MIR-1-producing *K. pneumoniae* as a positive result in the first assay but not in the second (Table 1).

As previously reported, class A and B carbapenemases yielded stronger results compared to class D enzymes regardless of the MICs attained for carbapenems (Table 1) (Österblad et al., 2014, Pasteran, Veliz, Ceriana, Lucero, Rapoport, Albornoz, Gomez and Corso, 2015, Pires, Novais and Peixe, 2013). Nevertheless, OXA-48 producers usually yielded stronger results with Blue-Carba than Carba-NP (e.g., 6 *vs*. 3 with "+++" for OP1 during the second assay, respectively). This difficult detection of OXA-48-like enzymes with Carba-NP is potentially linked to the B-PERII buffer. β-lactamases with lower imipenem hydrolytic efficiency produce less metabolites to overcome the buffer effect yielding weaker results. This has been reported as "buffer inhibition" which also justifies a different extraction solution used in the CarbaAcineto-NP that is mainly designed to detect OXA-type carbapenemases in *Acinetobacter* spp. (Dortet et al., 2014, Österblad, Hakanen and Jalava, 2014).

Interestingly, when comparing the agreement between the two tests considering only positive *vs.* negative results, the tests exhibit an almost perfect agreement [Kappa=0.91 (CI 95% 0.87-0.95)], emphasizing that both can be used to detect CPE given their high sensitivities and specificities. Additionally, this also highlights that the decreased cost of Blue-Carba can be extremely important in low income settings (Yusuf, Van Der Meeren, Schallier and Piérard, 2014).

Several potential sources of error have been identified. In our experience: *i*) the lack of standardization of the inoculum; *ii*) improper homogenization of the inoculum in the test solutions (Österblad, Hakanen and Jalava, 2014); and *iii*) improper storage of the test reagents (especially imipenem) can be linked to underperformance of both tests. Moreover, to improve detection, it is also suggested to increase the inoculum in either tests and also to perform them from specific media types and/or brands (Österblad, Hakanen and Jalava, 2014, Pires, Novais and Peixe, 2013, Tijet, Boyd, Patel, Mulvey and Melano, 2013). Despite the strong critics by some authors (Tijet, Boyd, Patel, Mulvey and Melano, 2013), it is undeniable that both methods can prove as an important clinical and epidemiological tool to be implemented in microbiology diagnostic labs. Additionally, the development of Carba-NP has encouraged the scientific community to improve and develop further quick alternative methods (Bakour et al., 2015, Bogaerts et al., 2015, Pasteran et al., 2015).

In conclusion, we demonstrated that both in-house Carba-NP and Blue-Carba tests are high sensitive and specific and thus suitable for rapid detection of CPE with an almost perfect agreement between the two tests. The simplicity of both tests makes them suitable for unexperienced operators readily identify carbapenemase production. Increasing the awareness of the possible errors on the test preparation and the

improvement of the protocol by standardizing the inoculum could be very important for increased sensitivity and specificity values.

This work was supported by the Swiss National Science Foundation (SNF; grant number 32003B_153377 to AE). João Pires is a PhD student (2014-2017) supported by the SNF. We thank Nadia Wohlwend and Lea Hirzberger for the technical help.

155 **REFERENCES**

156 Bakour, S., Garcia, V., Loucif, L., Brunel, J.M., Gharout-Sait, A., Touati, A., Rolain,
157 J.M., 2015. Rapid identification of carbapenemase-producing *Enterobacteriaceae*,
158 *Pseudomonas aeruginosa* and *Acinetobacter baumannii* using a modified Carba NP test.
159 New Microbes and New Infections. 7, 89-93.

160 Bogaerts, P., Yunus, S., Massart, M., Huang, T., Glupczynski, Y., 2015. Validation of a
161 new electrochemical assay (BYG test) for the rapid laboratorydetection of
162 carbapenemase-producing *Enterobacteriaceae*, 25th European Congress of Clinical
163 Microbiology and Infectious Diseases (ECCMID), Copenhagen, Denmark.

164 Dortet, L., Bréchard, L., Cuzon, G., Poirel, L., Nordmann, P., 2014. Strategy for Rapid
165 Detection of Carbapenemase-Producing *Enterobacteriaceae*. Antimicrobial Agents and
166 Chemotherapy. 58, 2441-2445.

167 Dortet, L., Poirel, L., Errera, C., Nordmann, P., 2014. CarbAcineto NP Test for Rapid
168 Detection of Carbapenemase-Producing *Acinetobacter* spp. Journal of Clinical
169 Microbiology. 52, 2359-2364.

170 Endimiani, A., Rossano, A., Kunz, D., Overesch, G., Perreten, V., 2012. First
171 countrywide survey of third-generation cephalosporin-resistant *Escherichia coli* from
172 broilers, swine, and cattle in Switzerland. Diagnostic Microbiology and Infectious
173 Disease. 73, 31-38.

174 Giani, T., Conte, V., Mandalà, S., D'Andrea, M.M., Luzzaro, F., Conaldi, P.G., Grossi,
175 P., Rossolini, G.M., 2014. Cross-Infection of Solid Organ Transplant Recipients by a
176 Multidrug-Resistant *Klebsiella pneumoniae* Isolate Producing the OXA-48
177 Carbapenemase, Likely Derived from a Multiorgan Donor. Journal of Clinical
178 Microbiology. 52, 2702-2705.

179 Hrabák, J., Chudáčkova, E., Papagiannitsis, C.C., 2014. Detection of carbapenemases in
180 *Enterobacteriaceae*: a challenge for diagnostic microbiological laboratories. Clinical
181 Microbiology and Infection. 20, 839-853.

182 Mammeri, H., Guillon, H., Eb, F., Nordmann, P., 2010. Phenotypic and Biochemical
183 Comparison of the Carbapenem-Hydrolyzing Activities of Five Plasmid-Borne AmpC
184 β-Lactamases. Antimicrobial Agents and Chemotherapy. 54, 4556-4560.

185 Nordmann, P., Poirel, L., Dortet, L., 2012. Rapid Detection of Carbapenemase-
186 producing *Enterobacteriaceae*. Emerging Infectious Disease journal. 18, 1503.

187 Novais, Â., Brilhante, M., Pires, J., Peixe, L., 2015. Evaluation of the Recently
188 Launched Rapid Carb Blue Kit for Detection of Carbapenemase-Producing Gram-
189 Negative Bacteria. Journal of Clinical Microbiology. 53, 3105-3107.

190 Österblad, M., Hakanen, A.J., Jalava, J., 2014. Evaluation of the Carba NP Test for
191 Carbapenemase Detection. Antimicrobial Agents and Chemotherapy. 58, 7553-7556.

192 Pasteran, F., Tijet, N., Melano, R.G., Corso, A., 2015. A simplified protocol of the
193 Carba NP test for enhanced detection of carbapenemase producers direct from bacterial
194 cultures. Journal of Clinical Microbiology.

195 Pasteran, F., Veliz, O., Ceriana, P., Lucero, C., Rapoport, M., Albornoz, E., Gomez, S.,
196 Corso, A., 2015. Evaluation of the Blue-Carba Test for Rapid Detection of
197 Carbapenemases in Gram-Negative Bacilli. Journal of Clinical Microbiology. 53, 1996-
198 1998.

199 Pilo, P., Vogt, D., Origgi, F.C., Endimiani, A., Peterson, S., Perreten, V., 2015. First
200 report of a multidrug-resistant *Klebsiella pneumoniae* of sequence type 11 causing
201 sepsis in a free-ranging beaver (Castor fiber). Environmental Microbiology Reports. 7,
202 351-353.

203 Pires, J., Novais, Â., Peixe, L., 2013. Blue-Carba, an Easy Biochemical Test for
204 Detection of Diverse Carbapenemase Producers Directly from Bacterial Cultures.
205 Journal of Clinical Microbiology. 51, 4281-4283.

206 Poirel, L., Nordmann, P., 2015. Rapidec Carba NP Test for Rapid Detection of
207 Carbapenemase Producers. Journal of Clinical Microbiology. 53, 3003-3008.

208 Principe, L., Bracco, S., Conte, V., Mauri, C., Giani, T., Pini, B., Rossolini, G.M.,
209 Luzzaro, F., 2015. *Klebsiella pneumoniae* produttore di NDM-1: primi casi di
210 importazione dall'Africa, XLV Congresso Nazionale AMCLI, Associazione
211 Microbiologi Clinici Italiani, Rimini, Italy.

212 Seiffert, S.N., Perreten, V., Johannes, S., Droz, S., Bodmer, T., Endimiani, A., 2014.
213 OXA-48 Carbapenemase-Producing *Salmonella enterica* Serovar Kentucky Isolate of
214 Sequence Type 198 in a Patient Transferred from Libya to Switzerland. Antimicrobial
215 Agents and Chemotherapy. 58, 2446-2449.

216 Seiffert, S.N., Tinguely, R., Lupo, A., Neuwirth, C., Perreten, V., Endimiani, A., 2013.
217 High Prevalence of Extended-Spectrum-Cephalosporin-Resistant *Enterobacteriaceae* in
218 Poultry Meat in Switzerland: Emergence of CMY-2- and VEB-6-Possessing *Proteus*
219 *mirabilis*. Antimicrobial Agents and Chemotherapy. 57, 6406-6408.

220 Tängdén, T., Giske, C.G., 2015. Global dissemination of extensively drug-resistant
221 carbapenemase-producing *Enterobacteriaceae*: clinical perspectives on detection,
222 treatment and infection control. Journal of Internal Medicine. 277, 501-512.

223 Tijet, N., Boyd, D., Patel, S.N., Mulvey, M.R., Melano, R.G., 2013. Evaluation of the
224 Carba NP Test for Rapid Detection of Carbapenemase-Producing *Enterobacteriaceae*
225 and *Pseudomonas aeruginosa*. Antimicrobial Agents and Chemotherapy. 57, 4578-
226 4580.

227 Vasoo, S., Cunningham, S.A., Kohner, P.C., Simner, P.J., Mandrekar, J.N., Lolans, K.,
228 Hayden, M.K., Patel, R., 2013. Comparison of a Novel, Rapid Chromogenic
229 Biochemical Assay, the Carba NP Test, with the Modified Hodge Test for Detection of
230 Carbapenemase-Producing Gram-Negative Bacilli. Journal of Clinical Microbiology.
231 51, 3097-3101.

Yusuf, E., Van Der Meeren, S., Schallier, A., Piérard, D., 2014. Comparison of the Carba NP test with the Rapid CARB Screen Kit for the detection of carbapenemase-producing *Enterobacteriaceae* and *Pseudomonas aeruginosa*. Eur J Clin Microbiol Infect Dis. 33, 2237-2240.

Table 1. Results obtained for the Carba NP and Blue-Carba tests performed using a collection of well-characterized strains (30 CPE and 33 non-CPE)

Acquired β-lactamases	Species (No. of strains with the same assay results)	Carba NP test						Blue-Carba test						MIC (µg/ml)			Reference or ATCC strain
		Assay 1			Assay 2			Assay 1			Assay 2						
		OP1	OP2	OP3	OP1	OP2	OP3	OP1	OP2	OP3	OP1	OP2	OP3	IMP	ERT	MEM	
Carbapenemase producers [a]																	
Class A (n=5)																	
KPC-2	*K. pneumoniae* (n=3)	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	≥8	≥64	≥64	This study
	K. pneumoniae (n=1)	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	++	+++	1	16	4	This Study
	K. pneumoniae (n=1)	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	++	++	1	8	2	ATCC BAA-1705
Class B (n=11)																	
IMP-1	*K. pneumoniae* (n=1)	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	16	64	32	This Study
NDM-1	*K. pneumoniae* (n=5)	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	≥1	≥4	≥2	This Study, (Principe et al., 2015)
	K. pneumoniae (n=1)	+++	+++	+++	+++	+++	+++	+++	+++	+++	++	+++	++	≥64	≥64	≥64	This Study
	E. coli (n=1)	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	16	≥64	≥64	This study
	E. coli (n=1)	++	++	++	++	++	++	+++	+++	+++	+++	+++	+++	8	≥64	≥64	ATCC BAA-2452
	E. cloacae (n=1)	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	16	64	64	This Study
VIM-1	*K. pneumoniae* (n=1)	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	8	0.5	1	This Study
VIM-2	*K. pneumoniae* (n=1)	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	++	64	≥64	≥64	This Study
Class D (n=10)																	
OXA-48	*K. pneumoniae* (n=1)	+	+	+	+	+	+	+++	+++	+++	+++	+++	+++	4	32	16	This Study
	K. pneumoniae (n=1)	++	++	++	++	+++	+++	+++	+++	+++	+++	+++	++	4	64	4	This Study
	K. pneumoniae (n=1)	+	++	+	++	+	++	++	++	+++	++	+++	++	4	≥8	≥16	This study
	K. pneumoniae (n=1)	+++	+++	++	+++	+++	++	+++	+++	+++	+++	++	+++	4	≥8	2	This Study
	K. pneumoniae (n=1)	++	++	+	++	++	+	+++	+++	+++	++	++	++	0.5	0.5	≤0.5	This Study
	K. pneumoniae (n=1)	++	++	++	+	++	+	++	+++	++	+++	+++	++	8	>= 8	2	(Giani et al., 2014)
	K. pneumoniae (n=1)	++	++	++	++	+++	++	++	++	++	++	++	++	4	>= 8	2	(Giani et al., 2014)
	E.coli (n=1)	+++	+++	++	+++	+++	++	+++	+++	+++	++	++	++	0.5	4	4	This Study
	E.coli (n=1)	+	+	+	++	++	++	++	++	++	+++	+++	+++	1	4	1	This Study
	Salmonella Kentucky (n=1)	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	≤0.25	1	≤0.5	(Seiffert et al., 2014)
Class B + class D (n=3)																	
NDM-1 + OXA-48	*C. freundii* (n=1)	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	++	4	≥8	2	This Study
	K. pneumoniae (n=2)	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	+++	≥4	≥4	≥16	This Study
Non-carbapenemase																	
Class A (n=9)																	
CTX-M-1	*E. coli* (n=2)	-	-	-	-	-	-	-	-	-	-	-	-	≤0.25	≤0.25	≤0.5	(Endimiani et al., 2012)
CTX-M-1-like	*E. coli* (n=1)	-	-	-	-	-	-	-	-	-	-	-	-	≤0.25	≤0.25	≤0.5	This Study
CTX-M-15-like	*K. oxytoca* (n=1)	-	-	-	-	-	-	-	-	+	-	-	-	≤0.25	≤0.25	≤0.5	This Study
SHV-12	*E. coli* (n=2)	-	-	-	-	-	-	-	-	-	-	-	-	≤0.25	≤0.25	≤0.5	(Endimiani et al., 2012)
TEM-52	*E. coli* (n=2)	-	-	-	-	-	-	-	-	-	-	-	-	≤0.25	≤0.25	≤0.5	
VEB-6	*P. mirabilis* (n=1)	-	-	-	-	-	-	-	-	-	-	-	-	≤0.25	≤0.25	≤0.5	(Seiffert et al., 2013)
Class C (n=10)																	
ACT-1	*E. coli* (n=1)	-	-	-	-	-	-	+	+	+	+	+	+	≤0.25	≤0.25	≤0.5	b
CMY-2	*E. coli* (n=4)	-	-	-	-	-	-	-	-	-	-	-	-	≤0.25	≤0.25	≤0.5	(Endimiani et al., 2012)
	P. mirabilis (n=1)	-	-	-	-	-	-	-	-	-	-	-	-	2	≤0.25	≤0.5	This Study
DHA-1	*E. coli* (n=1)	-	-	-	-	-	-	-	-	-	-	-	-	≤0.25	≤0.25	≤0.5	This Study
	K. pneumoniae (n=1)	-	-	-	-	-	-	-	-	-	-	-	-	≤0.25	0.5	≤0.5	(Pilo et al., 2015)
FOX-1	*E. coli* (n=1)	-	-	-	-	-	-	-	-	-	-	-	-	≤0.25	≤0.25	≤0.5	b
MIR-1	*K. pneumoniae* (n=1)	-	-	-	-	-	-	+	+	+	-	-	-	≤0.25	≤0.25	≤0.5	b
Class A + class C (n=1)																	
CTX-M-15-like + CMY-2	*E. coli* (n=1)	-	-	-	-	-	-	-	-	-	-	-	-	≤0.25	≤0.25	≤0.5	This Study
No Acquired β-lactamases																	
	C. koseri (n=1)	-	-	-	-	-	-	-	-	-	-	-	+	≤0.25	≤0.25	≤0.5	This Study
	C. koseri (n=1)	-	-	-	-	-	-	-	-	-	-	-	-	≤0.25	0.5	≤0.5	This Study
	E. coli (n=2)	-	-	-	-	-	-	-	-	-	-	-	-	≤0.25	≤0.25	≤0.5	ATCC 25922, (Endimiani et al., 2012)
	E. coli (n=1)	-	-	-	-	+	-	-	-	-	-	-	-	≤0.25	≤0.25	≤0.5	This Study
	E. aerogenes (n=1)	-	-	-	-	-	-	+	+	+	-	-	-	1	0.75	≤0.5	This Study
	E. cloacae (n=1)	-	-	-	-	-	-	-	-	+	-	-	-	≤0.25	2	≤0.5	This Study
	K. pneumoniae (n=5)	-	-	-	-	-	-	-	-	-	-	-	-	≤1	≤8	≤0.5	ATCC BAA-1706, This Study
	K. pneumoniae (n=1)	-	-	-	-	-	+	-	-	-	-	-	-	≤0.25	≤0.25	≤0.5	This Study

Note. "+++", strong positive; "++", positive; "+", weak positive; "-", negative; IMP, imipenem; ERT, ertapenem; MEM, meropenem

[a] Only carbapenemase genes are shown; [b] A kind gift from Robert A. Bonomo, Cleveland, OH, USA.